Boehringer Ingelheim said Wednesday that sales of prescription medicines climbed 12 percent in the first half of the year to 6.1 billion euros ($7.2 billion), boosted by the company's diabetes portfolio and the of idiopathic pulmonary fibrosis treatment Ofev. Boehringer Ingelheim's overall revenue rose 27 percent to 9.2 billion euros ($10.9 billion).

The drugmaker noted that sales from its diabetes products, which it markets together with Eli Lilly, jumped 59 percent in the six-month period to 1.2 billion euros ($1.4 billion). Meanwhile, revenue from Ofev surged 72 percent to 429 million euros ($508.2 million).

Boehringer Ingelheim added that it continues to expect a "considerable" year-on-year increase in currency-adjusted net sales for 2017.